PLUS1
37.34
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| REGENXBIO Inc | RGNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.43 | 1.16% | 37.34 | 37.08 | 39.18 | 38.06 | 36.91 | 18:01:16 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 35.05 | 45.00 | 9.95 | 22.11% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,714 | 380,602 | $ 38.11 | $ 14,503,442 | 402,547 | 20.03 - 55.23 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:38:49 | 30,329 | $ 37.34 | USD |
REGENXBIO Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.39B | 37.24M | 36.78M | $ 35.23M | $ - | -2.59 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 14.00 | 1.20% |
REGENXBIO News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/02/2020 | 16:37 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/02/2020 | 16:37 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/02/2020 | 16:36 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/02/2020 | 16:35 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/02/2020 | 16:34 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/02/2020 | 16:34 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/02/2020 | 16:33 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGNX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 39.40 | 39.49 | 35.50 | 37.34 | 509,286 | -2.06 | -5.23% |
| 1 Month | 40.64 | 44.375 | 34.86 | 39.08 | 389,995 | -3.30 | -8.12% |
| 3 Months | 29.15 | 45.06 | 20.03 | 34.07 | 465,214 | 8.19 | 28.1% |
| 6 Months | 45.00 | 54.97 | 20.03 | 38.97 | 466,127 | -7.66 | -17.02% |
| 1 Year | 47.68 | 55.23 | 20.03 | 39.95 | 497,780 | -10.34 | -21.69% |
| 3 Years | 18.80 | 85.10 | 17.60 | 45.07 | 475,349 | 18.54 | 98.62% |
| 5 Years | 30.26 | 85.10 | 7.0701 | 40.22 | 370,324 | 7.08 | 23.4% |
REGENXBIO Description
| Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). |
